PMID- 11158861
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20190815
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
VI  - 37
IP  - 1 Suppl 2
DP  - 2001 Jan
TI  - The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding 
      Survival) protocol: a double-blind, placebo-controlled trial in patients with 
      esrd.
PG  - S48-53
AB  - The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)-mediated 
      lowering of serum cholesterol has been associated with a significant reduction in 
      cardiovascular morbidity and mortality. Recent studies suggest that additional 
      non-lipid lowering effects (eg, endothelial stabilization, anti-inflammatory, 
      antithrombogenic) may be important in modulating their effectiveness. 
      Dyslipidemia is common in end-stage renal disease (ESRD), and hemodialysis 
      patients have increased cardiovascular morbidity and mortality. Cerivastatin, a 
      new statin with powerful low-density lipoprotein-cholesterol (LDL-C) lowering 
      capabilities, possesses some unique non-LDL-C-mediated properties that may 
      contribute to a reduction of coronary events in the patient with ESRD. The 
      primary objective of this multicenter multinational study of 1,054 hemodialysis 
      patients is to compare 2 years of treatment with cerivastatin (0.4 mg/d) versus 
      placebo on the composite clinical event rate of myocardial infarction, sudden 
      cardiac death, ischemic stroke, and the need for coronary arterial bypass graft 
      (CABG) or percutaneous transluminal coronary angioplasty (PTCA) procedures in 
      these patients. Changes in lipids, inflammatory proteins including heat stable 
      C-reactive protein (hsCRP), interleukin-6 (IL-6), oncostatin-M, intracellular 
      adhesion molecule-1 (ICAM-1) and monocyte-chemoattractant protein-1 (MCP-1), as 
      well as markers of cardiac muscle pathology, such as troponin I and troponin T, 
      will be assessed in a subset of patients. This study is the first of its kind to 
      assess the effect of a statin on the reduction of cardiovascular morbidity and 
      mortality in an incident hemodialysis population. It will determine whether 
      treatment with cerivastatin can effectively reduce the significant cardiovascular 
      morbidity and mortality.
FAU - Keane, W F
AU  - Keane WF
AD  - Department of Medicine, Hennepin County Medical Center, University of Minnesota 
      Medical School, Minneapolis, MN, USA. g.macgregor@sghms.ac.uk
FAU - Brenner, B M
AU  - Brenner BM
FAU - Mazzu, A
AU  - Mazzu A
FAU - Agro, A
AU  - Agro A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyridines)
RN  - AM91H2KS67 (cerivastatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Area Under Curve
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Heart/drug effects/physiopathology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Kidney Failure, Chronic/*drug therapy/metabolism/therapy
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Pyridines/pharmacokinetics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Renal Dialysis
MH  - Research Design
MH  - Survival Analysis
EDAT- 2001/02/13 11:00
MHDA- 2001/05/11 10:01
CRDT- 2001/02/13 11:00
PHST- 2001/02/13 11:00 [pubmed]
PHST- 2001/05/11 10:01 [medline]
PHST- 2001/02/13 11:00 [entrez]
AID - S0272-6386(01)84851-4 [pii]
AID - 10.1053/ajkd.2001.20739 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 2001 Jan;37(1 Suppl 2):S48-53. doi: 10.1053/ajkd.2001.20739.